Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05893979 · ClinicalTrials.gov registry record · NA
Myopia Control Spectacle Lens Cessation Study
A NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.
- Active
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 8
- Study locations
NCT05893979: Active NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.
NCT05893979 is a NA study of Myopia and Juvenile Myopia that is active but no longer recruiting, run by SightGlass Vision. The registered enrollment target is 90 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (66% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05893979, a NA study of Myopia and Juvenile Myopia, is active but no longer recruiting, sponsored by SightGlass Vision.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 8
- Study locations
Study Summary
To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.
Primary Outcome
Change in cSER
Conditions Studied
Interventions
- DEVICE Spectacle Lenses
Study Locations (8)
California
- Golden Optometric Group - Whittier
Florida
- Omega Vision Center PA - Longwood
Kansas
- Kannarr Eye Care - Pittsburg
Missouri
- Advanced Eyecare PC - Raytown
New York
- Sacco Eye Group - Vestal
Tennessee
- Total Eye Care - Memphis
Texas
- Vision Optique - Houston
Utah
- William J Bogus, OD, FAAO - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What the registry record for NCT05893979 still lists
NCT05893979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (66% lower).
The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which Spectacle Lenses is the first listed.
NCT05893979 lists 8 locations in 8 states (California, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT05893979 about?
NCT05893979 is a clinical study titled "Myopia Control Spectacle Lens Cessation Study". To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.
What is the current status of trial NCT05893979?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-06-23. Estimated completion is 2026-07-31.
What conditions does trial NCT05893979 study?
This clinical trial studies the following conditions: Myopia, Juvenile Myopia, Myopia Progression.
What interventions are being tested in trial NCT05893979?
The interventions under investigation include: Spectacle Lenses (DEVICE).
Who is sponsoring clinical trial NCT05893979?
This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05893979 being conducted?
This trial has 8 study locations across California, Florida, Kansas, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05893979's enrollment target sits among peer trials
90 41st of 90 higher than 47 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI